Next-Generation Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation, Systems, Bioinformatics, Sequencing Services) Application (Clinical, Research) End User

Description

List of Tables

Next-Generation Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation [DNA Extraction, Library Preparation, Automation], Systems, Bioinformatics, Sequencing Services) Application (Clinical, Research) End User-Global Forecast to 2031

The global next-generation sequencing (NGS) market is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The growth of the NGS market is driven by the rising cancer prevalence & the increasing application of NGS in cancer treatment and research, partnerships between NGS service providers & pharmaceutical companies, technological advancements in NGS, the growing demand for optimized & streamlined NGS workflows, the declining costs of genome sequencing, technological advancements in sequencing procedures, technological advancements in NGS informatics solutions, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory & reimbursement scenarios for NGS-based diagnostic tests.

Furthermore, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, collaborations between vendors to develop library preparation protocols, the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories, and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the players operating in the NGS market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global next-generation sequencing (NGS) market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.).

Among the offerings studied in this report, in 2024, the commercial sequencing/outsourced services segment is expected to account for the largest share of 38.0% of the market. The large market share of this segment can be attributed to the benefits offered by NGS service providers, including quick results, cost-effectiveness, and a wide array of services available for various applications.

Among the applications studied in this report, in 2024, the research & other applications segment is expected to account for the largest share of 62.2% of the next-generation sequencing (NGS) market. The large share of the segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the increasing use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 43.5% of the next-generation sequencing (NGS) market. The large market share of this segment can be attributed to the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of next-generation sequencing products among pharmaceutical & biotechnology companies.

An in-depth analysis of the geographical scenario of the global next-generation sequencing (NGS) market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 48.7% of the next-generation sequencing (NGS) market. Additionally, in 2024, the U.S. is expected to account for the largest share of the next-generation sequencing (NGS) market in North America. North America's large market share is attributed to the favorable government initiatives for genomic research, growing applications of sequencing-based research, presence of leading providers of next-generation sequencing technologies in the region, increasing research investments by pharmaceutical and biopharmaceutical companies, declining cost of sequencing coupled with the rising availability of advanced sequencing products and solutions, increasing cancer prevalence, and favorable reimbursement scenario in the region.

Scope of the Report:

Next-Generation Sequencing (NGS) Market Assessment-by Offering

Sample Preparation
- Kits & Reagents
Nucleic Acid Extraction and Amplification
Library Preparation
DNA Library Preparation
RNA Library Preparation
Quality Control
Other Reagents (1)
- Workstations/Robotic Platforms for Library Preparation
Sequencing
- NGS Systems
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing (SMRT)
DNA Nanoball (DNB) Sequencing
Other Technologies (2)
- Services (3)
Data Analysis/Bioinformatics
- Software
By Type
Data Analysis Software
Data Interpretation and Reporting Tools
Data Storage and Computing Tools
Laboratory Information Management Systems (LIMS)
By Deployment Mode
Web and Cloud-based
On-premise
- NGS Informatics Services (4)
Commercial Sequencing/ Outsourced Services
- Targeted Sequencing Services
- RNA Sequencing Services
- Whole Genome Sequencing Services
- De Novo Sequencing Services
- Exome Sequencing Services
- ChIP Sequencing Services
- Methyl Sequencing Services
- Other Commercial Sequencing Services (5)

Next-Generation Sequencing (NGS) Market Assessment-by Application

Research & Other Applications
- Drug Discovery
- Agriculture & Animal Research
- Other Applications (6)
Clinical Applications
- Reproductive Health Diagnosis
- Oncology
- Infectious Diseases
- Other Clinical Applications (7)

Next-Generation Sequencing (NGS) Market Assessment-by End User

Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Academic Institutes & Research Centers
Other End Users (8)

Note: 1. Other Reagents include dilution buffers, DNA standards, target enrichment kits/reagents, and other reagents required to support the NGS sample preparation workflow

2. Other Technologies include Nanopore sequencing & Avidity Sequencing Technology

3. Services include support services, such as the upgradation of software, customer support, equipment training, monitoring, installation services, and more

4. NGS informatics services include support services, such as bioinformatics data analysis services, bioinformatics consulting services, bioinformatics training, and IT professional services.

5. Other Commercial Sequencing Services include degradome sequencing, ribosome profiling, amplicon sequencing, CRISPR validation, viral genome sequencing, and immunogenomics services

6. Other Applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies

7. Other Clinical Applications include detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses

8. Other End Users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

Next-Generation Sequencing (NGS) Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Spain
- Rest of Europe (RoE)
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041274

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Impact Analysis of Market Dynamics
  - 4.2.1.1. Rising Cancer Prevalence & Increasing Application of NGS in Cancer Treatment and Research Driving Market Growth
  - 4.2.1.2. Availability of Alternative Technologies Restraining Market Growth
  - 4.2.1.3. Increasing Application of NGS in Personalized Medicine Generating Growth Opportunities for Market Players
  - 4.2.1.4. Data Storage, Handling, Interpretation, and Confidentiality Concerns Expected to Remain a Major Challenge for Market Stakeholders
- 4.2.2. Factor Analysis
4.3. Industry Trends
- 4.3.1. Increasing Partnerships & Collaborations Among NGS Solution Providers to Expand and Advance Product Offerings
- 4.3.2. Development of Portable Sequencing Technologies
- 4.3.3. Increasing Demand for NGS Automation
4.4. Pricing Analysis
- 4.4.1. NGS Instruments and Consumables
- 4.4.2. NGS Services
4.5. Regulatory Analysis
- 4.5.1. NGS Instruments & Consumables
  - 4.5.1.1. North America
    - 4.5.1.1.1. U.S.
    - 4.5.1.1.2. Canada
  - 4.5.1.2. Europe
  - 4.5.1.3. Asia-Pacific
    - 4.5.1.3.1. China
    - 4.5.1.3.2. Japan
    - 4.5.1.3.3. India
  - 4.5.1.4. Latin America
  - 4.5.1.5. Middle East
- 4.5.2. NGS Informatics
4.6. Case Studies/Use Cases
- 4.6.1. Case Study A
- 4.6.2. Case Study B
- 4.6.3. Case Study C
- 4.6.4. Case Study D
4.7. Porter's Five Forces Analysis
- 4.7.1. Bargaining Power of Buyers
- 4.7.2. Bargaining Power of Suppliers
- 4.7.3. Threat of Substitutes
- 4.7.4. Threat of New Entrants
- 4.7.5. Degree of Competition

5. Next-Generation Sequencing (NGS) Market Assessment - by Offering

5.1. Overview
5.2. Sample Preparation
- 5.2.1. Kits & Reagents
  - 5.2.1.1. Nucleic Acid Extraction and Amplification
  - 5.2.1.2. Library Preparation
    - 5.2.1.2.1. DNA Library Preparation
    - 5.2.1.2.2. RNA Library Preparation
  - 5.2.1.3. Quality Control
  - 5.2.1.4. Other Kits & Reagents
- 5.2.2. NGS Workstations
5.3. Sequencing
- 5.3.1. NGS Systems
  - 5.3.1.1. Sequencing by Synthesis
  - 5.3.1.2. Ion Semiconductor Sequencing
  - 5.3.1.3. Single-Molecule Real-Time Sequencing (SMRT)
  - 5.3.1.4. DNA Nanoball (DNB) Sequencing
  - 5.3.1.5. Other Technologies
- 5.3.2. Consumables
- 5.3.3. Services
5.4. Data Analysis/Bioinformatics
- 5.4.1. Software
  - 5.4.1.1. Software Market, by Type
    - 5.4.1.1.1. Data Analysis Software
    - 5.4.1.1.2. Data Interpretation and Reporting Tools
    - 5.4.1.1.3. Data Storage and Computing Tools
    - 5.4.1.1.4. Laboratory Information Management Systems (LIMS)
  - 5.4.1.2. Software Market, by Deployment Mode
    - 5.4.1.2.1. Web and Cloud-Based
    - 5.4.1.2.2. On-Premise
- 5.4.2. NGS Informatics Services
5.5. Commercial Sequencing/Outsourced Services
- 5.5.1. Targeted Sequencing Services
- 5.5.2. RNA Sequencing Services
- 5.5.3. De Novo Sequencing Services
- 5.5.4. Exome Sequencing Services
- 5.5.5. Chip Sequencing Services
- 5.5.6. Methyl Sequencing Services
- 5.5.7. Whole Genome Sequencing Services
- 5.5.8. Other Commercial Sequencing Services

6. Next-Generation Sequencing (NGS) Market Assessment - by Application

6.1. Overview
6.2. Research & Other Applications
- 6.2.1. Drug Discovery
- 6.2.2. Agriculture & Animal Research
- 6.2.3. Other Applications
6.3. Clinical Applications
- 6.3.1. Oncology
- 6.3.2. Reproductive Health
- 6.3.3. Infectious Diseases
- 6.3.4. Other Clinical Applications

7. Next-Generation Sequencing (NGS) Market Assessment - by End User

7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Hospitals & Diagnostic Laboratories
7.4. Academic Institutes & Research Centers
7.5. Other End Users

8. Next-Generation Sequencing (NGS) Market Assessment - by Geography

8.1. Overview
8.2. North America
- 8.2.1. U.S.
- 8.2.2. Canada
8.3. Europe
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
- 8.5.1. Brazil
- 8.5.2. Mexico
- 8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa

9. Competition Analysis

9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
- 9.4.1. Industry Leaders
- 9.4.2. Market Differentiators
- 9.4.3. Vanguards
- 9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
- 9.5.1. Instrument & Consumables
- 9.5.2. Data Analysis/Bioinformatics
- 9.5.3. Commercial Sequencing/Outsourced Services
- 9.5.4. NGS Workstations

10. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

10.1. Illumina, Inc.
10.2. Thermo Fisher Scientific Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. Eurofins Scientific Se
10.5. Beijing Genomics Institute (BGI)
10.6. Qiagen N.V.
10.7. Agilent Technologies, Inc.
10.8. Revvity, Inc.
10.9. Pacific Biosciences of California Inc.
10.10. Danaher Corporation
10.11. Oxford Nanopore Technologies Plc.
10.12. Tecan Group Ltd.
10.13. Hamilton Company
10.14. Hudson Robotics
10.15. LGC Limited
10.16. Eppendorf AG
10.17. Novogene Co., Ltd.
10.18. Dnastar, Inc.
10.19. Fabric Genomics, Inc.
10.20. MGI Tech Co., Ltd.
10.21. Quest Diagnostics Incorporated

(*Note: SWOT Analysis Provided for Top 5 Companies*)

11. Appendix

11.1. Available Customization
11.2. Related Reports